Kodiak Gas Servicesの空売り状況は、投資家がKodiak Gas Servicesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Kodiak Gas Services (NYSE:KGS) 株価情報, 空売り情報

Kodiak Gas Services

Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to primarily fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.

Kodiak Gas Services Inc

Kingspan Group PLC

KINGSPAN GROUP UNSP/ADR by Kingspan Group plc.

KINGMAN MINERALS LTD by Kingman Minerals Ltd.

Kingman Minerals Ltd

Cantor Fitzgerald analyst Matthew Prisco reiterates Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with a Overweight and maintains $300 price target.

News

Price Target

Reiteration

Analyst Ratings

AVGO

Cantor Fitzgerald Reiterates Overweight on Broadcom, Maintains $300 Price Target

U.S. stocks traded higher this morning, with the Dow Jones jumping more than 500 points on Friday.
Following the market opening Friday, the Dow traded up 1.29% to 42,867.21 while the NASDAQ gained 1.34% to 19,557.93. The S&amp;P 500 also rose, gaining, 1.17% to 6,008.98.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45811726/cramer-says-hes-not-going-to-really-want-to-do-a-lot-of-china-right-now">Cramer Says He&#8217;s &#8216;Not Going To Really Want To Do A Lot Of China Right Now&#8217;</a>
Leading and Lagging Sectors Energy shares jumped by 1.8% on Friday.
In trading on Friday, utilities stocks rose by just 0.2%.
Top Headline
The U.S. labor market showed surprising resilience in May, as job creation outpaced forecasts and wage growth accelerated, defying concerns that mounting tariffs and trade friction would drag down economic momentum.
Nonfarm payrolls rose by 139,000 in May, beating consensus expectations of 130,000, according to data released Friday by the Bureau of Labor Statistics.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>WEBUY GLOBAL LTD. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBUY#NASDAQ">WBUY</a>) shares shot up 88% to $8.93.</li>
<li>Shares of Davis Commodities Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTCK#NASDAQ">DTCK</a>) got a boost, surging 80% to $1.0850 after the company announced approval of $30 million fundraising plan to establish Bitcoin reserves to strengthen asset allocation.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares were also up, gaining 57% to $3.7299 after the company announced it entered into a definitive agreement to sell its Venus Hair business to Meta Healthcare Group.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Northann Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCL#NYSE">NCL</a>) shares dropped 41% to $0.79.</li>
<li>Shares of EPWK Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPWK#NASDAQ">EPWK</a>) were down 37% to $1.0499. EPWK officially kicked off its international business &#8211; EPWK International with the launch of the English site (intl.epwk.com).</li>
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) was down, falling 27% to $22.48.</li>
</ul>
Commodities In commodity news, oil traded up 1.8% to $64.54 while gold traded up 0.1% at $3,376.50.
Silver traded up 1.7% to $36.400 on Friday, while copper rose 0.1% to $4.94.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.3%, while Spain's IBEX 35 Index rose 0.4%. London's FTSE 100 rose 0.3%, Germany's DAX 40 gained 0.1% and France's CAC 40 rose 0.2% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei gaining 0.50%, Hong Kong's Hang Seng Index falling 0.48%, China's Shanghai Composite gaining 0.04% and India's BSE Sensex gaining 0.92%.
Economics
<ul class="wp-block-list">
<li>Nonfarm payrolls rose by 139,000 in May, beating consensus expectations of 130,000, according to data released Friday by the Bureau of Labor Statistics.</li>
<li>Average hourly earnings rose 0.4% in May, the strongest monthly increase since January and ahead of the expected 0.3%.</li>
<li>The US unemployment rate came in steady at 4.2% for May.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45813240/top-2-energy-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Energy Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Markets

Trading Ideas

DTCK

EPWK

Nuveen Insured California Premium Fund Ii

VERA

VERO

WBUY

Dow Jumps Over 500 Points; Nonfarm Payrolls Top Estimates

William Blair analyst Adam Klauber initiates coverage on Allstate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) with a Sector Outperform rating.

Initiation

William Blair Initiates Coverage On Allstate with Sector Outperform Rating

<a href="https://truthsocial.com/@realDonaldTrump/114636734825372318">https://truthsocial.com/@realDonaldTrump/114636734825372318</a>

General

President Trump Posts On Truth Social "If "Too Late" at the Fed would CUT, we would greatly reduce interest rates, long and short, on debt that is coming due. Biden went mostly short term. There is virtually no inflation (anymore), but if it should come back, RAISE "RATE" TO COUNTER. Very Simple!!! He is costing our Country a fortune. Borrowing costs should be MUCH LOWER!!!"

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that may <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">cause vision loss</a>.
Novo Nordisk A/S's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide, a GLP-1 receptor agonist, is the&nbsp;active substance&nbsp;in certain medicines used for <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">diabetes and obesity</a> (Ozempic, Rybelsus, and Wegovy).
After reviewing all available data on NAION with semaglutide, including data from non-clinical studies,&nbsp;clinical trials, post-marketing surveillance and the medical literature,&nbsp;the committee on Friday <a target="_blank" href="https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy" rel="noreferrer noopener">concluded</a> that NAION is a very rare side effect of semaglutide (meaning it may affect up to 1 in 10,000 people taking semaglutide).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45418556/novo-nordisks-ozempic-weight-loss-jabs-could-boost-uk-economy-by-6-billion-study-finds" rel="noreferrer noopener">Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds</a>
Results from several large epidemiological studies suggest that exposure to semaglutide in adults with type 2 diabetes is associated with an approximately two-fold increase in the risk of developing NAION compared with people not taking the medicine.
This corresponds to approximately one additional case of NAION per 10,000 person-years of treatment; one person-year corresponds to one person taking semaglutide for one year.
Data from&nbsp;clinical trials&nbsp;also point to a slightly higher risk of developing the condition in people taking semaglutide compared with people taking a placebo (a dummy treatment).
Therefore, EMA has recommended that the&nbsp;product information&nbsp;for semaglutide medicines be updated to include NAION as a side effect with a frequency of ‘very rare.'
In December, a study conducted in Denmark and Norway revealed a potential link between the use of semaglutide for type 2 diabetes and an increased risk of non-arteritic anterior <a target="_blank" href="https://www.benzinga.com/24/12/42489755/novo-nordisks-ozempic-potentially-linked-to-rare-vision-loss-risk-but-study-concludes-absolute-increase-in-risk-minimal" rel="noreferrer noopener">ischemic optic neuropathy (NAION)</a>.
Additionally, New research suggests that GLP-1 receptor agonists, widely prescribed for diabetes and weight loss, may significantly raise the risk of age-related macular degeneration in older diabetic patients.
A <a target="_blank" href="https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2834967?guestAccessKey=3bb97cc4-36f2-4679-807b-4741de2fa139&amp;utm_source=for_the_media&amp;utm_medium=referral&amp;utm_campaign=ftm_links&amp;utm_content=tfl&amp;utm_term=060525" rel="noreferrer noopener">study</a> published on Thursday in JAMA Ophthalmology by the University of Toronto researchers warns of a potential downside: increased risk of neovascular age-related macular degeneration (nAMD) in diabetic users.
nAMD is&nbsp;a severe form of age-related macular degeneration characterized by the growth of abnormal blood vessels in the back of the eye.
Analyzing medical data from over 1 million Ontario residents with diabetes, researchers identified 46,334 patients prescribed GLP-1 RAs, most of whom were taking semaglutide—likely Ozempic, since Wegovy was only recently approved in Canada.
Patients on these medications were matched with participants not on GLP-1 RAs, sharing similar demographics and health profiles, and tracked for three years.
The study found that diabetic patients taking GLP-1 RAs for at least six months had double the risk of developing neovascular AMD compared to non-users.
Over a mean follow-up period of 2.4 years, 0.2% of the GLP-1 RA cohort progressed to nAMD compared with only 0.1% of control participants, resulting in an increased hazard for nAMD of 2.21 for the GLP-1 RA cohort.
The risk was also highest in those with the longest duration of exposure.
The Guardian report <a target="_blank" href="https://www.theguardian.com/society/2025/jun/05/weight-loss-drugs-risk-of-eye-damage-diabetic-patients-study" rel="noreferrer noopener">added</a> that those on the medications for more than 30 months had over three times the risk. The risk was even greater in older patients and those with a prior stroke.
Recent findings from the 2025 American Clinical Society of Oncology annual conference suggested that patients using weight loss drugs, including Ozempic, were about 33% more likely to be diagnosed with kidney cancer compared to matched individuals <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45757157/whats-going-on-with-novo-nordisk-shares-today" rel="noreferrer noopener">not using the medication</a>.
Price Action: NVO stock is up 2.45% at $74.43&nbsp;at the last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45407486" target="_blank" rel="noreferrer noopener">Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Biotech

Large Cap

Health Care

Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say

Wedbush analyst Daniel Ives maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Outperform and raises the price target from $80 to $120.

RBRK

Wedbush Maintains Outperform on Rubrik, Raises Price Target to $120

The S&amp;P 500 has been on a rollercoaster in 2025, but one investor&#8217;s recent Reddit <a href="https://www.reddit.com/r/StockMarket/comments/1l1n91t/the_market_is_incapable_of_falling_who_keeps/">post</a> summed up the confusion felt by many: &#8220;The market is incapable of falling. Who keeps buying the dip?&#8221;
<h2 class="wp-block-heading">Frustration Grows As Dips Keep Getting Bought</h2>
The post, shared in the r/StockMarket subreddit, got hundreds of responses from retail investors, passive index fund buyers, and even skeptics of the entire system. The frustration? Even with inflation, tariffs, political chaos, and a declining dollar, the market <a href="https://www.benzinga.com/markets/equities/25/06/45739065/sp-500-reverses-short-term-downtrend-after-april-lows-technical-evidence-shows-recovery-is-real-and-not-a-bull-trap-or-bear-market-rally">keeps rebounding</a> almost instantly from minor pullbacks.
&#8220;It literally hasn&#8217;t stopped since this post. Unbelievable,&#8221; one person wrote. Another chimed in, &#8220;The market exists solely to personally f&#x2A;&#x2A;&#x2A; you and your investments.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
</ul>
As shown in the screenshot posted with the thread, the S&amp;P 500 was barely down 0.066% on Monday, hovering around 5,907. Traders saw the same choppy but stubbornly buoyant pattern all day. Despite intraday lows near 5,861, it climbed back up, finishing the day at 5,935.
<h2 class="wp-block-heading">Is It 401(k)s, Algos Or The Fed?</h2>
Some blamed automatic retirement contributions for the relentless buying. &#8220;Every two weeks, millions are putting money <a href="https://www.benzinga.com/money/what-is-a-401k">into their 401(k)</a>. This has to help, no?&#8221; one commenter asked. Another added that yes, it&#8217;s &#8220;your 401(k) buying the dip.&#8221;
Others turned to conspiracy. &#8220;Every time the <a href="https://www.benzinga.com/markets/bonds/25/05/45604132/10-year-yield-tops-455-despite-trumps-eu-tariff-delay-as-bond-market-signals-fiscal-concerns">10-year bond yield spikes</a>, it&#8217;s instantly bought up. Or, look at the Nasdaq or Dow Jones charts. Anytime they start to fall, it&#8217;s bought up. This type of behavior is not organic, it is clearly a managed system,&#8221; wrote one skeptical poster.
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
Meanwhile, others chalked it up to sheer irrationality. &#8220;It is said that the market will move in a way that will cause the maximum pain to the greatest number of people,&#8221; one investor said, citing the infamous <a href="https://www.benzinga.com/general/education/14/11/4988931/can-an-idea-known-as-maximum-pain-theory-make-you-money-1">&#8220;max pain&#8221; theory in options trading</a>.
<h2 class="wp-block-heading">Dollar Weakness And Big Tech Carry The Day</h2>
Some argue that the market isn't actually rising—the <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45714416/former-treasury-secretary-larry-summers-warns-the-dollar-is-starting-to-trade-like-a-latin-american-currency-greenback-going-from-safe-haven-to-risk-asset">dollar is just falling</a>. &#8220;It takes more dollars to represent the value of stocks, gold, etc.,&#8221; one poster explained. &#8220;SPY should be around 5,450 if adjusted for the stronger dollar we had.&#8221;
Tech earnings are also doing heavy lifting. &#8220;The top 10 weights of the S&amp;P 500 account for about 33% of its value,&#8221; one commenter pointed out. &#8220;[Amazon, Microsoft, Nvidia, Meta] all posted very impressive earnings.&#8221;
See Also: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
<h2 class="wp-block-heading">Still, Fear Lurks</h2>
Despite the calm exterior, not everyone is convinced the rally is real. &#8220;I think if we get a crash, it will be utterly insane. It&#8217;s all automated. The panic will go mad if something really bad happens,&#8221; one investor warned.
Another said it more plainly: &#8220;This same comment was made in June 2007. Sigh.&#8221;
For now, investors continue to wait for a real correction. But with paychecks still flowing into index funds, a record $6.95 trillion in cash on the sidelines, and passive investing dominating the market, the dip keeps getting bought, for better or worse.
As one user joked, &#8220;It&#8217;s me. I invested 15 euros today. You don&#8217;t need to say thank you.&#8221;
Read Next: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
Image: Shutterstock

The Stock Market Just Won't Drop, Says One Investor. He's Asking The Question Everyone's Thinking—'Who Keeps Buying The Dip?'

<a href="https://truthsocial.com/@realDonaldTrump/posts/114636703372425608">https://truthsocial.com/@realDonaldTrump/posts/114636703372425608</a>

President Trump Posts On Truth Social ""Too Late" at the Fed is a disaster! Europe has had 10 rate cuts, we have had none. Despite him, our Country is doing great. Go for a full point, Rocket Fuel!"

Wedbush analyst Daniel Ives maintains Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a Neutral and lowers the price target from $100 to $85.

DOCU

Wedbush Maintains Neutral on Docusign, Lowers Price Target to $85

BDMD

Baird Medical Shares Halted On Circuit Breaker To The Downside, Stock Now Down 6.18%

Northann Shares Halted On Circuit Breaker To The Downside, Stock Now Down 41.5%

Alphawave Semi&nbsp;on Thursday announced the&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/tsmc" rel="noreferrer noopener">successful&nbsp;tape out</a> of one of UCIe IP subsystem on Taiwan Semiconductor Manufacturing Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) 2-nm process, supporting 36G die-to-die data rates.
The solution fully integrates with&nbsp;Taiwan Semiconductor&#8217;s Chip-on-Wafer-on-Substrate (CoWoS)&nbsp;advanced packaging technology, unlocking bandwidth density and scalability for <a target="_blank" href="https://www.businesswire.com/news/home/20250605712350/en/Alphawave-Semi-Tapes-Out-Breakthrough-36G-UCIe-IP-on-TSMC-2nm-Unlocking-Foundational-AI-Platform-IP-on-Nanosheet-Processes" rel="noreferrer noopener">advanced chiplet architectures</a>.
This milestone builds on the&nbsp;recent release&nbsp;of the Alphawave Semi AI Platform,&nbsp;proving readiness to support the future of disaggregated SoCs&nbsp;and scale-up infrastructure for hyperscale AI and HPC workloads.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/45801113/keysight-synopsys-team-up-to-fast-track-rf-migration-to-taiwan-semis-n4p-process" target="_blank" rel="noreferrer noopener">Keysight, Synopsys Team Up To Fast-Track RF Migration To Taiwan Semi&#8217;s N4P Process</a>
Alphawave Semi is advancing key ecosystem collaborations to enable technologies, leveraging&nbsp;D2D-based open chiplet interoperability&nbsp;to drive a broader AI connectivity platform for the industry.
Intel Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) has tapped <a target="_blank" href="https://www.benzinga.com/media/25/04/44962945/intel-taps-taiwan-semiconductor-for-advanced-2nm-process-for-ai-powered-chips-report" rel="noreferrer noopener">its long-term supplier</a>,&nbsp;Taiwan Semiconductor, for its&nbsp;advanced 2-nm process.
Intel and Taiwan Semiconductor are collaborating on a 2nm product to manufacture the compute tile for Intel&#8217;s next-gen Nova Lake PC processors, which are expected in 2026.
Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) is already a client of Taiwan Semiconductor&#8217;s 2-nm process.
According to Ming-Chi Kuo, Apple Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)&nbsp;upcoming&nbsp;iPhone 18&nbsp;lineup <a target="_blank" href="https://www.benzinga.com/25/03/44453733/apples-iphone-18-to-get-massive-boost-with-2nm-a20-chiptsmcs-yields-surge-past-70-says-top-analyst" rel="noreferrer noopener">will likely feature</a>&nbsp;Taiwan Semiconductor&#8217;s 2-nm A20 chip.
Taiwan Semiconductor <a target="_blank" href="https://www.benzinga.com/markets/asia/25/05/45466444/to-serve-exploding-ai-chip-demand-taiwan-semiconductor-plans-9-advanced-factories" rel="noreferrer noopener">plans to build</a> five wafer fabs in Kaohsiung to produce chips using 2-nm and A16 technology. It expects its 2-nm technology to start commercializing in the second half of 2025 at two new fabs in Hsinchu and Kaohsiung.
The company will also add an advanced chip packaging facility using chip-on-wafer-on-substrate (CoWoS) technology.
Price Action: TSM stock is up 0.24% to $203.83 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45748492/taiwan-semiconductors-japan-chip-factory-faces-delays-while-us-expansion-takes-priority" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor&#8217;s Japan Chip Factory Faces Delays, While US Expansion Takes Priority</a></li>
</ul>
Photo by wakamatsu via Shutterstock

Tech

AAPL

INTC

Taiwan Semiconductor Powers Alphawave's 2nm Chip Breakthrough For Faster AI And HPC Connectivity

The Generation Essentials Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 30.5%

Keybanc analyst Jackson Ader initiates coverage on Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) with a Sector Weight rating.

FSLY

Keybanc Initiates Coverage On Fastly with Sector Weight Rating

Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) posted better-than-expected first-quarter results after <a href="https://www.benzinga.com/quote/RBRK/earnings">Thursday&#8217;s closing bell</a>.
Rubrik reported quarterly losses of 15 cents per share, which beat the analyst consensus estimate of losses of 32 cents. Quarterly revenue came in at $278.48 million, which beat the Street estimate of $260.35 million.
"Our outstanding first-quarter results not only surpassed all guided metrics but also underscore the power of our focused innovation and execution. We are winning the cyber resilience market, and I believe that our opportunity is bigger than ever," said Bipul Sinha, Rubrik's CEO.
Rubrik raised its fiscal 2026 adjusted EPS guidance to a range of losses of $1.02 to losses of 96 cents, versus the estimate of losses of $1.15. The company raised its fiscal revenue outlook to between $1.18 billion and $1.19 billion, versus the $1.16 billion estimate.
Rubrik shares gained 2.6% to trade at $100.93 on Friday.
These analysts made changes to their price targets on Rubrik following earnings announcement.
<ul class="wp-block-list">
<li>Rosenblatt analyst Blair Abernethy maintained Rubrik with a Buy rating and raised the price target from $82 to $110.</li>
<li>Keybanc analyst Eric Heath maintained the stock with an Overweight rating and boosted the price target from $98 to $113.</li>
</ul>
Considering buying RBRK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06093408/image-100-1024x585.png" alt="" class="wp-image-941256" style="width:649px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06093408/image-100-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06093408/image-100-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06093408/image-100-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06093408/image-100.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock">Jim Cramer Likes Dominion Energy, But Isn&#8217;t &#8216;A Fan&#8217; Of This Real Estate Stock</a> </li>
</ul>
Photo via Shutterstock

These Analysts Boost Their Forecasts On Rubrik After Better-Than-Expected Q1 Results

WIIM

VERO stock has given up its prior loss. Venus Concept shares were trading lower after the company announced it entered into a definitive agreement to sell its Venus Hair business to Meta Healthcare Group.

Scotiabank analyst Louise Chen upgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Sector Perform to Sector Outperform and maintains the price target from $80 to $80.

Upgrades

SRPT

Scotiabank Upgrades Sarepta Therapeutics to Sector Outperform, Maintains Price Target to $80

Cibus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced today that its most recent trait for its herbicide tolerance trait (HT2) in Canola has been designated as "not regulated" by the United States Department of Agriculture's Animal and Plant Health Inspection Service (USDA-APHIS) Biotechnology Regulatory Services (BRS) as Plant Pests or Which There is Reason to Believe Are Plant Pests, as described in 7 CFR part 340.

CBUS

Cibus' Herbicide Tolerance Canola Trait HT2 Designated As Not Regulated Under USDA's Biotechnology Regulations

Citigroup analyst Eric Wolfe downgrades American Homes 4 Rent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMH#NYSE">AMH</a>) from Buy to Neutral and maintains the price target from $41 to $41.

Downgrades

Citigroup Downgrades American Homes 4 Rent to Neutral, Maintains Price Target to $41

The Children&#8217;s Place, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) will release its first-quarter earnings results after the <a href="https://www.benzinga.com/quote/PLCE/earnings">closing bell on Friday, June 6.</a>
Analysts expect the Secaucus, New Jersey-based company to report quarterly loss at 51 cents per share. Children&#8217;s Place projects to report quarterly revenue at $260.62 million, compared to $267.88 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 11, the company reported that net sales for the fourth quarter fell 10.2% year-over-year to $408.6 million from $455.0 million in the year-ago period.
Children&#8217;s Place shares gained 3.6% to close at $6.59 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/plce/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>UBS analyst Jay Sole maintained a Neutral rating and cut the price target from $11 to $9 on March 4, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating with a price target of $9 on May 22, 2024. This analyst has an accuracy rate of 61%.</li>
<li>B. Riley Securities analyst Jeff Lick upgraded the stock from Sell to Neutral and cut the price target from $12 to $7 on April 24, 2024. This analyst has an accuracy rate of 74%.</li>
</ul>
Considering buying PLCE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/PLCE/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="564" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06044033/image-86-1024x564.png" alt="" class="wp-image-940881" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06044033/image-86-1024x564.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06044033/image-86-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06044033/image-86-768x423.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06044033/image-86.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

PLCE

Children's Place Likely To Report Lower Q1 Revenue; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Offerings

Press Releases

EQT completes public offering of common stock of Kodiak Gas Services

Kodiak Gas Services Announces Quarterly Dividend and Fourth Quarter and Full Year 2024 Earnings Release and Conference Call Schedule

EQT completes sale of common stock of Kodiak Gas Services pursuant to Rule 144

Kodiak Gas Services Announces 2024 Schedule K-1 Investor Tax Packages for CSI Compressco LP Are Available Online

Kodiak Gas Services Reports Fourth Quarter and Full Year 2024 Results; Provides Full Year 2025 Guidance

Kodiak Gas Services Breaks Ground on State-of-the-Art Facilities in Midland and Pecos

Kodiak Gas Services Announces Increased Quarterly Dividend and First Quarter 2025 Earnings Release and Conference Call Schedule

Kodiak Gas Services Announces First Quarter 2025 Financial Results, Provides Updated Full Year 2025 Guidance

Kodiak Gas Services Announces Closing of Sale of Common Stock by Selling Stockholder Pursuant to Rule 144

EQT completes sale of common stock of Kodiak Gas Services

ProFrac Holding Corp. - Class A Common Stock

ProFrac Holding

Atlas Energy Solutions

Aris Water Solutions, Inc. Class A Common Stock

Aris Water Solutions

Archrock

Baker Hughes

ChampionX

Flowco Holdings Inc. Class A Common Stock

Flowco Holdings

TechnipFMC

Halliburton

Helix Energy Solutions Group, Inc. Common Stock

Helix Energy Solns Gr

Innovex International

Liberty Energy

Oceaneering International, Inc. Common Stock

Oceaneering International

ProPetro Holding

Solaris Energy Infrastructure, Inc. Class A Common Stock

Solaris Energy

Schlumberger

Tidewater

Tenaris

USA Compression Partners, LP Common Units Representing Limited Partner Interests

Comments

Kodiak Gas Services

空売り

Kodiak Gas Services (NYSE:KGS) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル